These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16391801)

  • 41. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.
    Lukashev AN; Fuerer C; Chen MJ; Searle P; Iggo R
    Hum Gene Ther; 2005 Dec; 16(12):1473-83. PubMed ID: 16390278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.
    Guise CP; Grove JI; Hyde EI; Searle PF
    Gene Ther; 2007 Apr; 14(8):690-8. PubMed ID: 17301844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
    Palmer DH; Milner AE; Kerr DJ; Young LS
    Br J Cancer; 2003 Sep; 89(5):944-50. PubMed ID: 12942130
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.
    Lemmon MJ; van Zijl P; Fox ME; Mauchline ML; Giaccia AJ; Minton NP; Brown JM
    Gene Ther; 1997 Aug; 4(8):791-6. PubMed ID: 9338007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase.
    Friedlos F; Court S; Ford M; Denny WA; Springer C
    Gene Ther; 1998 Jan; 5(1):105-12. PubMed ID: 9536271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway.
    Cui W; Gusterson B; Clark AJ
    Gene Ther; 1999 May; 6(5):764-70. PubMed ID: 10505099
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.
    Bridgewater JA; Springer CJ; Knox RJ; Minton NP; Michael NP; Collins MK
    Eur J Cancer; 1995 Dec; 31A(13-14):2362-70. PubMed ID: 8652270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Demonstration of the activation of prodrug CB 1954 using human DT-diaphorase mutant Q104Y-transfected MDA-MB-231 cells and mouse xenograft model.
    Wu K; Eng E; Knox R; Chen S
    Arch Biochem Biophys; 2001 Jan; 385(1):203-8. PubMed ID: 11361019
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice.
    Bequet-Romero M; Ayala M; Acevedo BE; Rodríguez EG; Ocejo OL; Torrens I; Gavilondo JV
    Angiogenesis; 2007; 10(1):23-34. PubMed ID: 17273909
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas.
    Li J; Tan H; Dong X; Xu Z; Shi C; Han X; Jiang H; Krissansen GW; Sun X
    Dig Liver Dis; 2007 Jun; 39(6):557-65. PubMed ID: 17374519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
    Helsby NA; Ferry DM; Patterson AV; Pullen SM; Wilson WR
    Br J Cancer; 2004 Mar; 90(5):1084-92. PubMed ID: 14997211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of the CDT6/ANGX gene on tumour growth in immune competent mice.
    Bouïs D; Hospers GA; Meijer C; Dam W; Peek R; Mulder NH
    In Vivo; 2003; 17(2):157-61. PubMed ID: 12792978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
    Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
    Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combining gene and immunotherapy for prostate cancer.
    Young JG; Green NK; Mautner V; Searle PF; Young LS; James ND
    Prostate Cancer Prostatic Dis; 2008; 11(2):187-93. PubMed ID: 17726452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector.
    Green NK; McNeish IA; Doshi R; Searle PF; Kerr DJ; Young LS
    Int J Cancer; 2003 Mar; 104(1):104-12. PubMed ID: 12532426
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.
    Prosser GA; Copp JN; Mowday AM; Guise CP; Syddall SP; Williams EM; Horvat CN; Swe PM; Ashoorzadeh A; Denny WA; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2013 Apr; 85(8):1091-103. PubMed ID: 23399641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
    Chen SH; Sun JM; Chen BM; Lin SC; Chang HF; Collins S; Chang D; Wu SF; Lu YC; Wang W; Chen TC; Kasahara N; Wang HE; Tai CK
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen.
    Bouquet C; Lamandé N; Brand M; Gasc JM; Jullienne B; Faure G; Griscelli F; Opolon P; Connault E; Perricaudet M; Corvol P
    Mol Ther; 2006 Aug; 14(2):175-82. PubMed ID: 16600689
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
    Palmer DH; Mautner V; Mirza D; Oliff S; Gerritsen W; van der Sijp JR; Hubscher S; Reynolds G; Bonney S; Rajaratnam R; Hull D; Horne M; Ellis J; Mountain A; Hill S; Harris PA; Searle PF; Young LS; James ND; Kerr DJ
    J Clin Oncol; 2004 May; 22(9):1546-52. PubMed ID: 15051757
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluating the abilities of diverse nitroaromatic prodrug metabolites to exit a model Gram negative vector for bacterial-directed enzyme-prodrug therapy.
    Chan-Hyams JVE; Copp JN; Smaill JB; Patterson AV; Ackerley DF
    Biochem Pharmacol; 2018 Dec; 158():192-200. PubMed ID: 30352235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.